GoAI
Get started
Sotera Health Company logo

Sotera Health Company

SHC

NASDAQHealthcareMedical - Diagnostics & Research

Open in GoAI

Previous close

$19.57

+$0.35 · +1.82%

Aug 21, 4:00 PM ET

Pre-market

$19.465

−$0.105 · -0.54%

Aug 24, 4:36 AM ET

SHC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

83

Deep Value

Momentum

59

Neutral

Sentiment

60

Mixed

Risk resilience

64

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing. Through its Nelson Labs division, Sotera Health conducts comprehensive microbiological and analytical chemistry analyses. Additionally, it offers specialized consulting to the medical device and biopharmaceutical industries. Sotera Health serves a diverse array of sectors, including medical device manufacturers, pharmaceutical companies, producers of food and agricultural products, and various commercial, advanced, and specialty application industries. Incorporated in 2017, the company was previously known as Sotera Health Topco, Inc., adopting its current name in October 2020.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
US
CEO
Alton E. Shader
Listed since
Nov 20, 2020
Employees
3,000

Market position

Day range

Current $19.57

52-week range

Current $19.57

Open
$19.30
Previous close
$19.22
Volume
2.35M
0.73× average
Average volume
3.22M
Average daily volume
Market cap
5.58B USD
Beta
1.78
Market reference 1
50-day average
$17.7424
+10.30% above average
200-day average
$16.6507
+17.53% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
6.94B USD
P/E (TTM)
34.14×
P/B (TTM)
8.4×
P/S (TTM)
4.59×
EV / EBITDA
15.68×
Earnings yield
1.56%
Free cash flow yield
2.98%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
54.72%
Operating margin
36.24%
Net margin
13.44%
Return on equity
12.86%
Return on assets
2.39%
Return on invested capital
6.83%

Financial health

Debt / equity
3.41×
Current ratio
2.46×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends64%32%0%-31%Gross margin, FY2021: 55.68%Gross margin, FY2022: 55.50%Gross margin, FY2023: 55.00%Gross margin, FY2024: 54.73%Gross margin, FY2025: 55.48%Operating margin, FY2021: 27.56%Operating margin, FY2022: 24.74%Operating margin, FY2023: 26.37%Operating margin, FY2024: 27.05%Operating margin, FY2025: 33.75%Net margin, FY2021: 12.55%Net margin, FY2022: -23.27%Net margin, FY2023: 4.90%Net margin, FY2024: 4.03%Net margin, FY2025: 6.70%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 55.68%. Gross margin FY2022 55.50%. Gross margin FY2023 55.00%. Gross margin FY2024 54.73%. Gross margin FY2025 55.48%. Operating margin FY2021 27.56%. Operating margin FY2022 24.74%. Operating margin FY2023 26.37%. Operating margin FY2024 27.05%. Operating margin FY2025 33.75%. Net margin FY2021 12.55%. Net margin FY2022 -23.27%. Net margin FY2023 4.90%. Net margin FY2024 4.03%. Net margin FY2025 6.70%.

Income trends

Revenue

1.16B USD+5.74%

Operating income

392.77M USD+31.97%

Net income

77.95M USD+75.57%
Income trends across reported periods1.3B USD744.46M USD185.59M USD−373.29M USDRevenue, FY2021: 931.48M USDRevenue, FY2022: 1B USDRevenue, FY2023: 1.05B USDRevenue, FY2024: 1.1B USDRevenue, FY2025: 1.16B USDOperating income, FY2021: 256.73M USDOperating income, FY2022: 248.35M USDOperating income, FY2023: 276.69M USDOperating income, FY2024: 297.63M USDOperating income, FY2025: 392.77M USDNet income, FY2021: 116.88M USDNet income, FY2022: −233.57M USDNet income, FY2023: 51.38M USDNet income, FY2024: 44.4M USDNet income, FY2025: 77.95M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 931.48M USD. Revenue FY2022 1B USD. Revenue FY2023 1.05B USD. Revenue FY2024 1.1B USD. Revenue FY2025 1.16B USD. Operating income FY2021 256.73M USD. Operating income FY2022 248.35M USD. Operating income FY2023 276.69M USD. Operating income FY2024 297.63M USD. Operating income FY2025 392.77M USD. Net income FY2021 116.88M USD. Net income FY2022 −233.57M USD. Net income FY2023 51.38M USD. Net income FY2024 44.4M USD. Net income FY2025 77.95M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.16B USD1.1B USD1.05B USD1B USD931.48M USD
Cost of goods sold518.08M USD498.15M USD472.13M USD446.68M USD412.81M USD
Gross profit645.53M USD602.3M USD577.16M USD557M USD518.67M USD
Selling, general, and administrative252.76M USD242.63M USD236.67M USD245.71M USD198.16M USD
Operating expenses252.76M USD304.67M USD300.47M USD308.65M USD261.94M USD
Interest expense155.72M USD164.69M USD142.88M USD80.14M USD74.19M USD
Depreciation and amortization139.03M USD163.64M USD157.93M USD145.55M USD150.9M USD
Operating income392.77M USD297.63M USD276.69M USD248.35M USD256.73M USD
Net income77.95M USD44.4M USD51.38M USD−233.57M USD116.88M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 2 misses, 2 met estimates
Average EPS surprise
+6.33%
11 comparable reports
Latest EPS result
0.26
Estimate 0.24 · Beat by 8.83%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.310.240.170.1Q1 '25MetQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 0.21, estimate 0.21, surprise 0.00%, Met estimate. Q2 2025, reported May 1, 2025: actual 0.14, estimate 0.12, surprise +16.67%, Beat. Q3 2025, reported Aug 8, 2025: actual 0.2, estimate 0.17, surprise +17.65%, Beat. Q4 2025, reported Nov 4, 2025: actual 0.26, estimate 0.22, surprise +18.18%, Beat. Q1 2026, reported Feb 24, 2026: actual 0.26, estimate 0.24, surprise +8.33%, Beat. Q2 2026, reported May 5, 2026: actual 0.18, estimate 0.17, surprise +5.88%, Beat. Q3 2026, reported Aug 6, 2026: actual 0.26, estimate 0.239, surprise +8.83%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 0.27, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates334.23M303.38M272.52M241.67MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual 290.2M USD, estimate 259.69M USD, surprise +11.75%, Beat. Q2 2025, reported May 1, 2025: actual 254.52M USD, estimate 276.95M USD, surprise -8.10%, Miss. Q3 2025, reported Aug 8, 2025: actual 294.34M USD, estimate 304.99M USD, surprise -3.49%, Miss. Q4 2025, reported Nov 4, 2025: actual 311.31M USD, estimate 299.56M USD, surprise +3.92%, Beat. Q1 2026, reported Feb 24, 2026: actual 303.44M USD, estimate 299.48M USD, surprise +1.32%, Beat. Q2 2026, reported May 5, 2026: actual 280.05M USD, estimate 270.78M USD, surprise +3.42%, Beat. Q3 2026, reported Aug 6, 2026: actual 321.38M USD, estimate 309.7M USD, surprise +3.77%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate 319.84M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$19.00

2.91% downside
Past 12 months12-month forecast

Price history unavailable

High $20.00Average $19.00Low $18.00

Rating distribution

12 ratings
Strong buy00%
Buy1192%
Hold18%
Sell00%
Strong sell00%

SHC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SHC

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Mid-Cap ETF logoiShares Core S&P Mid-Cap ETFIJH
Market value
172.46M
Weight
0.13%
AUM
125.92B USD
Expense ratio
0.05%
Price / 1D
$76.77+0.52%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
154.45M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
111.24M
Weight
0.06%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
64.47M
Weight
0.14%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
54.51M
Weight
0.06%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
State Street SPDR S&P MIDCAP 400 ETF Trust logoState Street SPDR S&P MIDCAP 400 ETF TrustMDY
Market value
37.33M
Weight
0.14%
AUM
26.72B USD
Expense ratio
0.23%
Price / 1D
$699.6+0.48%
iShares S&P Mid-Cap 400 Growth ETF logoiShares S&P Mid-Cap 400 Growth ETFIJK
Market value
29.08M
Weight
0.26%
AUM
10.95B USD
Expense ratio
0.16%
Price / 1D
$115.45+0.37%
State Street SPDR Portfolio S&P 400 Mid Cap ETF logoState Street SPDR Portfolio S&P 400 Mid Cap ETFSPMD
Market value
26.44M
Weight
0.14%
AUM
18.77B USD
Expense ratio
0.03%
Price / 1D
$67.27+0.52%

Continue in GoAI

Research SHC

research.disclaimer